ARYx Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARYX research report →
Price Chart
About the company
Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts.
- CEO
- Paul Goddard
- IPO
- 2007
- Employees
- 56
- HQ
- Fremont, CA, US
Get TickerSpark's AI analysis on ARYX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $16.73K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.15
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-31,238,000
- Net Income
- $-33,167,000-6.2%
- EPS
- $-1.21+26.7%
- OCF Growth
- +22.7%
- FCF Growth
- +23.4%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -7.55
- Avg Volume
- 1.84K
No earnings-call transcripts are available for ARYX yet.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 11 | Growth Equity Opportunities Fund, LLC | sell | 4,469,274 |
| Mar 10, 11 | DRANT RYAN D | sell | 4,469,274 |
| Mar 10, 11 | KOLLURI KRISHNA KITTU | sell | 4,469,274 |
| Mar 10, 11 | KERINS PATRICK J | sell | 4,469,274 |
| Sep 30, 10 | SIMON NICHOLAS J III | buy | 500,000 |
| Sep 30, 10 | MPM BIOVENTURES III-QP L.P. | buy | 500,000 |
| Sep 30, 10 | EVNIN LUKE | buy | 500,000 |
| Aug 13, 10 | EVNIN LUKE | buy | 500,000 |
| Aug 13, 10 | MPM BIOVENTURES III-QP L.P. | buy | 500,000 |
| Aug 13, 10 | SIMON NICHOLAS J III | buy | 500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARYX coverage
Recent articles, reports, and earnings notes.
No research on ARYX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARYX report →